Berlin - Delayed Quote • EUR Rocket Pharmaceuticals Inc (9IP1.BE) Follow 20.60 -0.01 (-0.05%) At close: April 26 at 8:30 PM GMT+2 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for 9IP1.BE 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: 9IP1.BE View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report? Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress 15 Best Strong Buy Stocks To Invest In Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) 7 Speculative Stocks to Double Your Money THIS Year Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)? Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) Shift From Loss To Profit
